Summary
54 / 100 · Bulios Score
What speaks for it
- Revenue grew by 32% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
What to watch
- The company made a loss over the last 12 months.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 20% a year over 5 years. Over the last 3 years it grew by 32% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $11.1M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 4
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $1 is 250% above today's price. 80% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Orthobiologics 54%
- Spinal Implant 32%
- License Revenue 14%
By region
- UNITED STATES 91%
- Non-US 8.6%
Orthobiologics brings in 54% of revenue.
Segments in detail